Search
Close this search box.

Alzheimer's

Deprescribing Education vs Usual Care for Patients with Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Trial

Elizabeth Bayliss, MD, MSPHSenior Investigator, Institute for Health Research, Kaiser Permanente ColoradoProfessor of Family Medicine, University of Colorado School of MedicineIMPACT Health Care Systems (HCS) CoreUSDeN Data and Resources Core Co-LeaderUSDeN Measures Working Group Leader Cynthia Boyd, MD, MPHDirector, Division of Geriatric Medicine and GerontologyProfessor of Medicine, Epidemiology and Health Policy and ManagementJohns Hopkins University […]

Deprescribing Education vs Usual Care for Patients with Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Trial Read More »

Beyond Study Design and Primary Outcomes: Lessons Learned from a Deprescribing Trial to Increase Cognitive Reserve

Presenter: Dr. Daniela Moga is an Associate Professor and Larry H. Spears Endowed Chair in Pharmacogenetics in the College of Pharmacy at University of Kentucky. April 12, 2022 | 2PM ET / 11AM PT The course of Alzheimer’s disease (AD) includes a 10–20-year preclinical period with progressive accumulation of amyloid β plaques and neurofibrillary tangles

Beyond Study Design and Primary Outcomes: Lessons Learned from a Deprescribing Trial to Increase Cognitive Reserve Read More »

Contact Us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.